Reference : Management of inflammatory bowel disease in pregnancy.
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
Human health sciences : Immunology & infectious disease
Management of inflammatory bowel disease in pregnancy.
Vermeire, Séverine mailto [Katholieke Universiteit Leuven - KUL > UZ Gasthuisberg > Gastroenterology > >]
Carbonnel, Franck mailto [CHU Jean Minjoz - Besançon > > Gastroentérologie et nutrition > >]
Coulie, Pierre mailto [Université Catholique de Louvain - UCL > de Duve Institute > Physiology and Immunology > >]
Geenen, Vincent mailto [Université de Liège - ULiège > > Centre d'immunologie >]
Hazes, Johanna M.W. mailto [> >]
Masson, Pierre mailto [Université Catholique de Louvain - UCL > de Duve Institut > > >]
de Keyser, Filip mailto [Ghent University > Rheumatology > > >]
LOUIS, Edouard mailto [Centre Hospitalier Universitaire de Liège - CHU > > Gastro-Entérologie-Hépatologie >]
Journal of Crohn's and Colitis
Yes (verified by ORBi)
[en] Colitis, Ulcerative/complications/drug therapy/therapy ; Crohn Disease/complications/drug therapy/therapy ; Female ; Fertility/drug effects ; Humans ; Immunosuppressive Agents/therapeutic use ; Inflammatory Bowel Diseases/complications/drug therapy/therapy ; Lactation/drug effects ; Male ; Pregnancy ; Pregnancy Complications/drug therapy/therapy ; Pregnancy Outcome
[en] BACKGROUND AND AIMS: Inflammatory bowel disease (IBD) is a chronic disease affecting mainly young people in their reproductive years. IBD therefore has a major impact on patients' family planning decisions. Management of IBD in pregnancy requires a challenging balance between optimal disease control and drug safety considerations. This article aims to provide a framework for clinical decision making in IBD based on review of the literature on pregnancy-related topics. METHODS: Medline searches with search terms 'IBD', 'Crohn's disease' or 'ulcerative colitis' in combination with keywords for the topics fertility, pregnancy, congenital abnormalities and drugs names of drugs used for treatment of IBD. RESULTS: IBD patients have normal fertility, except for women after ileal pouch-anal anastomosis (IPAA) and men under sulfasalazine treatment. Achieving and maintaining disease remission is a key factor for successful pregnancy outcomes in this population, as active disease at conception carries an increased risk of preterm delivery and low birth weight. Clinicians should discuss the need for drug therapy to maintain remission with their patients in order to ensure therapy compliance. Most IBD drugs are compatible with pregnancy, except for methotrexate and thalidomide. If possible, anti-TNF therapy should be stopped by the end of the second trimester and the choice of delivery route should be discussed with the patient. CONCLUSIONS: Disease control prior to conception and throughout pregnancy is the cornerstone of successful pregnancy management in IBD patients.
Researchers ; Professionals ; Students
Copyright (c) 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

Open access
IBD and pregnancy.pdfPublisher postprint363.35 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.